{"id":"NCT04124965","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","officialTitle":"A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-29","primaryCompletion":"2021-09-01","completion":"2021-09-01","firstPosted":"2019-10-14","resultsPosted":"2023-08-21","lastUpdate":"2023-09-05"},"enrollment":71,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Myasthenia Gravis"],"interventions":[{"type":"DRUG","name":"Rozanolixizumab","otherNames":["UCB7665"]}],"arms":[{"label":"Rozanolixizumab dosage regimen 1","type":"EXPERIMENTAL"},{"label":"Rozanolixizumab dosage regimen 2","type":"EXPERIMENTAL"}],"summary":"The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From Baseline until End of Study (up to Week 60)","effectByArm":[{"arm":"Rozanolixizumab ~7 mg/kg","deltaMin":76,"sd":null},{"arm":"Rozanolixizumab ~10 mg/kg","deltaMin":78.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":43,"countries":["United States","Canada","Czechia","Denmark","France","Germany","Italy","Japan","Poland","Russia","Spain","Taiwan"]},"refs":{"pmids":["40105996","37059507"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":50},"commonTop":["Headache","Diarrhoea","Blood immunoglobulin G decreased","Nausea","Pyrexia"]}}